CME online

in association with the 18th Annual World Congress on Insulin Resistance Diabetes and Cardiovascular Disease -WCIRDC

Heart Failure and Kidney Disease: The Next Epidemics

This is a CME Symposium Supported by an Educational Grant from AstraZeneca

Provided By:

This CME online educational activity is approved for a maximum of 2 AMA PRA Category 2 Credit(s) and ABIM MOC

Accreditation period: January 15, 2021 – January 15, 2022

To get started:

To Receive a Certificate for This CME Activity:

View the presentations in this CME activity and complete the evaluation. Your certificate will be emailed to you upon satisfactory completion of these documents.

Agenda

Introduction
Yehuda Handelsman, MD, Chair

Epidemiology and Traditional Management of HF and CKD
Maria Rosa Costanzo, MD

The Future Is Here: Contemporary Approach to HF with a Focus on HFrEF
Mikhail Kosiborod, MD

Revolution in the Management of Moderate to Severe CKD
Katherine Tuttle, MD

Impact of Recent CVOTs on Contemporary Guidelines for HF and CKD
Muthiah Vaduganathan, MD

Panel Discussion and Q&A: The Cardiorenal Syndrome - Is It More Than the Sum of the Individual Components?
Moderator: Peter McCullough, MD, PhD

Faculty

Peter A. McCullough, MD, MPH, FACC, FACP, FCCP, FAHA, FNKF, FCRSA

Vice Chief of Medicine
Baylor University Medical Center
Dallas, Texas

Yehuda Handelsman, MD, FNLA, FACP, MACE Chair

Medical Director & Principal Investigator, Metabolic Institute of America
Chair & Program Director: WCIRDC & HiD
President, Pacific Lipid Association
Past President AACE and ACE
Tarzana, California

Maria Rosa Costanzo, MD, FAHA, FACC, FESC

Past Medical Director, Heart Failure Research, Advocate Heart Institute
Medical Director, Edward Hospital Center for Advanced Heart Failure
Naperville, Illinois, U.S.A

Mikhail Kosiborod MD, FACC, FAHA

Professor of Medicine,
Saint Luke's Mid America Heart Institute
University of Missouri-Kansas City School of Medicine
Kansas City, Missouri

Muthiah Vaduganathan, MD, MPH

Cardiologist, Brigham and Women's Hospital,
Harvard Medical School
Boston, Massachusetts

Program Description

Heart failure (HF) and chronic kidney disease (CKD), share common pathophysiologic origins, including hypertension, inflammation, hyperglycemia and increased renin-angiotensin-aldosterone system activity. Though the risk of HF & CVD is 2–8 times higher if patients have diabetes and CKD, it is also prevailed in people with other cardiometabolic conditions. Of note over half of heart failure patients have moderate to severe CKD. The CardioRenal Syndrome represents and heightens the relationship of these tightly related conditions. In recent cardiovascular outcomes trials (CVOTs), sodium glucose cotransporter 2 (SGLT2) inhibitors showed a Primary and Secondary prevention of HF and CKD, and identified the benefit of SGLT2i in advanced CKD and in HF with reduced function. This symposium will examine emerging approaches to preventing HF & CKD in Diabetes, and the management of HFrEF and advanced CKD in people with and without DM. The value of the cardiorenal syndrome concept will be examined

Learning Objectives

Upon completion of this symposium, participants should be able to:

Describe the etiologic and pathophysiologic links between HF, CKD, and cardiometabolic disorders

Explain the gaps in traditional HF management specifically in HF with reduced function- HFrEF and in the management of moderate to severe CKD

Describe outcomes in trials with SGLT2 inhibitors involving patients with HFrEF and advanced CKD with and without type 2 diabetes and their impact on clinical practice

Examine whether the cardiorenal syndrome represents more than its individual components and design relevant therapeutic regimens for the syndrome

Target Audience

This educational initiative is designed for cardiologists, endocrinologists, nephrologists, family physicians, internists, diabetologists, nurse practitioners, physician assistants, diabetes educators, and other healthcare professionals interested in the pathophysiology, prevention, and treatment of diabetes, obesity, kidney disease, cardiovascular disease, and associated conditions, as well as the effect of these conditions on health and society.

CME Statement

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of PESI Inc., and Metabolic Endocrine Education Foundation (MEEF). PESI Inc., is accredited by the ACCME to provide continuing medical education for physicians.

PESI Inc., designated this enduring educational activity for a maximum of 2 AMA PRA Category 2 Credit(s) and ABIM MOC. Physicians should only claim credit commensurate with the extent of their participation in the activity.

For information please contact: [email protected] or 818 342 1889
This is a CME Program Supported by an Educational Grant from Astrazeneca